ABSTRACT
Epidermal growth factor receptor ( EGFR) is most popular in targeted therapy for non-small cell lung cancer ( NSCLC ) . In recent years, there have been a great number of molecular biology studies of EGFR. Radiotherapy is well-known as a traditional and important treatment for NSCLC, and the treatment outcome is associated with EGFR mutation and overexpression. Phase Ⅲ trials are needed to evaluate the effect of a combination of radiotherapy and EGFR-tyrosine kinase inhibitor ( EGFR-TKI) in the treatment of NSCLC. MicroRNAs ( miRNAs) can modulate tumor-associated gene expression and influence the biological process of tumor. Recent studies have demonstrated that miRNAs play a positive or negative role in EGFR mutation, EGFR-TKI treatment, and radiotherapy, which mechanism has been partially clarified. In this article, we review the research advances in the association of miRNAs with EGFR mutation, EGFR-TKI, and radiotherapy, so as to provide the latest evidence for the application of miRNAs in the combination of radiotherapy and EGFR-TKI for the treatment of NSCLC.
ABSTRACT
Epidermal growth factor receptor ( EGFR) is most popular in targeted therapy for non-small cell lung cancer ( NSCLC ) . In recent years, there have been a great number of molecular biology studies of EGFR. Radiotherapy is well-known as a traditional and important treatment for NSCLC, and the treatment outcome is associated with EGFR mutation and overexpression. Phase Ⅲ trials are needed to evaluate the effect of a combination of radiotherapy and EGFR-tyrosine kinase inhibitor ( EGFR-TKI) in the treatment of NSCLC. MicroRNAs ( miRNAs) can modulate tumor-associated gene expression and influence the biological process of tumor. Recent studies have demonstrated that miRNAs play a positive or negative role in EGFR mutation, EGFR-TKI treatment, and radiotherapy, which mechanism has been partially clarified. In this article, we review the research advances in the association of miRNAs with EGFR mutation, EGFR-TKI, and radiotherapy, so as to provide the latest evidence for the application of miRNAs in the combination of radiotherapy and EGFR-TKI for the treatment of NSCLC.
ABSTRACT
To observe the protective effect of takepron(lansoprazole)on the gastric mucosal lesion in rats and its mechanisms . Before gastric mucosal lesion was produced in rats with pure alcohol,takepron was administered into the gastric lumen, and N? nitro L arginine methyl ester(L NAME) and L arginine were injected intravenously. Gastric mucosal blood flow(GMBF)was assessed with laser Doppler flowmetry,gastric mucosal and serum NO - 2 /NO - 3 were measured by cadmium granulation reduction and colorimetric method,and the gastric mucosal ulcer index(UI),the degree of tissue necrosis and neutrophil infiltration were observed . The results showed that UI of the takepron group was much lower than that of the control group( P